TSH Variability of Patients Affected by Differentiated Thyroid Cancer Treated with Levothyroxine Liquid Solution or Tablet FormReportar como inadecuado




TSH Variability of Patients Affected by Differentiated Thyroid Cancer Treated with Levothyroxine Liquid Solution or Tablet Form - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

International Journal of Endocrinology - Volume 2017 2017, Article ID 7053959, 5 pages - https:-doi.org-10.1155-2017-7053959

Research Article

Department of Medical and Surgical Sciences, Endocrine and Metabolic Unit, Clinica Medica, 2nd Medicina, Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy

Department of Molecular and Translational Medicine, 3rd Division of General Surgery, Spedali Civili di Brescia, University of Brescia, 25123 Brescia, Italy

Department of Otorhinolaryngology, Spedali Civili di Brescia, 25123 Brescia, Italy

Correspondence should be addressed to Carlo Cappelli

Received 29 December 2016; Revised 13 March 2017; Accepted 22 March 2017; Published 9 May 2017

Academic Editor: Franco Veglio

Copyright © 2017 Carlo Cappelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Recent guidelines from the American Thyroid Association ATA indicate that, in many patients affected by differentiated thyroid cancer DTC, the serum TSH should be maintained between 0.1 and 0.5 mU-L. The purpose of this study was to evaluate the TSH variability of patients affected by DTC treated with liquid L-T4 formulation or in tablet form. Patients and Methods. Patients were eligible if a they were submitted to a total thyroidectomy and

I remnant ablation for DTC in our institution and b they were classified low-risk patients according to ATA guidelines 2009. Patients were randomized 1 : 1 to receive treatment of hypothyroidism with liquid L-T4 or tablet form. The first check-up evaluation was made from 8 to 12 months after

I remnant ablation. TSH values were established again after further 12 months. Results. A significant increase in TSH values median was observed in patients taking tablets TSH min–max: 0.28 0.1–0.45 versus 0.34 0.01–0.78 mIU-L, as compared to those taking liquid formulation TSH min–max: 0.28 0.1–0.47 versus 0.30 0.1–0.55 mIU-L, . Conclusions. The use of L-T4 liquid formulation, as compared to that of tablets, resulted in a significantly higher number of DTC patients maintaining TSH values in range for the ATA risk score, reducing TSH variability over the time.





Autor: Carlo Cappelli, Ilenia Pirola, Elena Gandossi, Claudio Casella, Davide Lombardi, Barbara Agosti, Fiorella Marini, Andrea De

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados